

The Study of Indigenous Phytotherapy with Modern Biomedical Research by Isolating, Screening, and Validating Bio-Active Compounds in Traditional Medicinal Plants

Priyanka¹, Dr. Arpana Sharma²

¹Research Scholar, Department of Botany, YBN University, Ranchi.

²Associate Professor, Department of Botany, YBN University, Ranchi.

Abstract

Indigenous phytotherapy is the practice of preventing, managing, and treating illnesses using native or local medicinal plants, guided by the traditional knowledge, cultural beliefs, and customary practices of indigenous communities. However, conventional natural product discovery often struggles with issues of rediscovery, compositional variability, complex synergistic mixtures, and mechanistic ambiguity. Bridging traditional ethnomedicine with contemporary biomedicine requires an integrated, multi-tiered framework termed "reverse pharmacology." Rather than treating natural extracts merely as random combinatorial libraries, modern biomedical pipelines interrogate ethnopharmacological preparations through an iterative workflow encompassing ethno-directed field bioprospecting, high-resolution multi-omics profiling, bio-chemometrics, and orthogonal fractionation. Bioassay-guided isolation is accelerated by coupling liquid chromatography-tandem mass spectrometry (LC-MS/MS), feature-based molecular networking, and nuclear magnetic resonance (NMR) spectroscopy with automated high-throughput and high-content phenotypic screening. Target engagement and mechanism of action are subsequently validated via chemical proteomics, cellular thermal shift assays, network pharmacology, and physiologically relevant animal models (including zebrafish and transgenic rodents). Crucially, this translational continuum depends on ethical benefit-sharing, legal harmonization, and strict conservation standards. This article details the analytical, screening, and validation methodologies necessary to translate Indigenous plant-derived pharmacophores into clinically viable therapeutics without divorcing them from their cultural and empirical heritage.

Key- Words: Indigenous Phytotherapy, Traditional Medicinal Plants, Biomedical Research, Nuclear Magnetic Resonance (NMR)

Introduction: The Interface of Indigenous Knowledge and Biomedicine:

Traditional medicine and Indigenous phytotherapy represent centuries of empirical clinical observation, offering an invaluable repository of bioactive chemical scaffolds. Throughout human history, plant secondary metabolites have served as the foundational armamentarium against infectious, inflammatory, and degenerative disorders. Major breakthroughs in modern pharmacotherapy—including the antimalarial artemisinin from *Artemisia annua*, the antimitotic paclitaxel from *Taxus brevifolia*, and the antihypertensive reserpine from *Rauwolfia serpentina*—originated directly from Indigenous health systems and ethnomedical observations (Leonti et al., 2017; Vaidya et al., 2018). Modern biomedical research is the multidisciplinary field of science dedicated to understanding biological processes, preventing disease, and developing new medical treatments and diagnostic tools. It applies the principles

of natural sciences—particularly biology, chemistry, and physics—directly to clinical medicine and public health. Unlike traditional medicine systems (like phytotherapy) that often rely on historical observation and whole-plant synergy, modern biomedical research is fundamentally rooted in the scientific method, molecular analysis, and data-driven clinical trials.

Despite this precedent, natural product drug discovery encountered significant bottlenecks during the late twentieth century. High-throughput screening (HTS) platforms within pharmaceutical pipelines increasingly prioritized synthetic combinatorial libraries over complex natural extracts. Crude botanical preparations were frequently abandoned due to:

1. Frequent re-isolation of known, ubiquitous compounds (e.g., polyphenols, common phytosterols).
2. Complex matrix effects and pan-assay interference compounds (PAINS) causing false-positive readouts.
3. Batch-to-batch chemical variability influenced by geographic, seasonal, and edaphic factors.
4. The reductionist premise of biomedical pharmacology ("one disease, one target, one drug"), which fails to capture multi-component phototherapeutic synergy.

Traditional medicinal plants are plant species that have been used for generations in indigenous, folk, and regional health systems to prevent, diagnose, or treat physical and mental illnesses. They contain naturally occurring bioactive compounds (phytochemicals) that exhibit therapeutic properties. These plants form the foundational basis of **indigenous phytotherapy** and established traditional medicine systems such as Ayurveda, Unani, Siddha, and various tribal healing practices across the globe. The emergence of modern analytical platforms, functional metabolomics, network pharmacology, and artificial intelligence has revived interest in Indigenous phytotherapy. Rather than treating ethnobotanical formulas as crude precursors waiting to be replaced by single synthetic derivatives, contemporary biomedical research pursues a bi-directional paradigm. On one hand, it isolates novel single-chemical entities for conventional target-based drug development; on the other, it standardizes multicomponent botanical drugs capable of addressing multifactorial pathologies via poly-pharmacology. Realizing this potential demands a rigorous workflow that bridges Indigenous discovery with standardized isolation, phenotypic screening, and mechanistic validation.

The Reverse Pharmacology Framework

Conventional forward drug discovery transitions linearly from target identification to in vitro screening, hit-to-lead optimization, preclinical animal models, and finally Phase I–III human clinical trials. This path is protracted, cost-intensive, and fraught with high clinical attrition rates due to unpredicted human toxicity or poor in vivo efficacy.

Conventional Drug Discovery:

Target Identification —> In Vitro HTS —> Lead Optimization —> Animal Tox/Efficacy
—> Phase I-III Trials

Reverse Pharmacology Discovery:

Documented Clinical/Ethnomedical Use → Standardized Formulations → Experimental Models → Target/Mechanism Deconvolution

Reverse pharmacology inverts this trajectory (Vaidya et al., 2018). It starts from documented human clinical use and centuries-old observational safety records. By beginning at the experiential endpoint, researchers bypass arbitrary chemical space and focus on extracts that already display physiological tolerance in humans.

Reverse pharmacology proceeds through three core phases:

- **Experiential Phase:** Rigorous documentation of ethnomedical applications, preparation rituals (decoctions, macerations, oils), solvent dynamics, dosage ranges, and perceived contraindications.
- **Exploratory Phase:** Standardization of plant vouchers, metabolomic fingerprinting, bioassay-guided fractionation, and phenotypic screening in cell and animal models to confirm efficacy and establish safety indices.
- **Experimental Phase:** Definitive chemical structural elucidation, target deconvolution via chemical proteomics, molecular modelling, and randomized clinical evaluation.

Methodological Tools for Extraction, Isolation, and Dereplication

1. Sustainable Extraction Technologies

Extracting active botanical constituents requires techniques that preserve thermolabile compounds and minimize environmentally destructive solvents:

- **Supercritical Fluid Extraction (SFE):** Utilizes supercritical CO₂ (often modified with trace ethanol or methanol) under controlled temperature and pressure. SFE provides high selectivity for non-polar and semi-polar lipophilic constituents (such as terpenoids and alkaloids) without leaving toxic solvent residues.
- **Pressurized Liquid Extraction (PLE) / Accelerated Solvent Extraction (ASE):** Uses conventional solvents at elevated temperatures (50–200°C) and pressures (10–15 MPa), significantly accelerating desorption kinetics, enhancing cell-wall permeability, and lowering extraction time.
- **Ultrasound-Assisted (UAE) and Microwave-Assisted Extraction (MAE):** UAE causes acoustic cavitation that disrupts botanical cell structures, whereas MAE produces dipole rotation and ionic conduction to heat the matrix internally, yielding high recovery of polar polyphenolic and glycosidic compounds.

2. Analytical Separation and Orthogonal Fractionation

Fractionating crude plant extracts into manageable sub-fractions without denaturing active complexes requires an orthogonal analytical cascade:

- **Centrifugal Partition Chromatography (CPC) and High-Speed Counter-Current Chromatography (HSCCC):** Support-free liquid-liquid partition techniques that


eliminate irreversible sample adsorption on solid stationary phases, ensuring near 100% compound recovery.

- **Medium-Pressure Liquid Chromatography (MPLC):** Employed for rapid, high-capacity initial bulk fractionation of crude extracts across reverse-phase (C_{18}), normal-phase (silica), or hydrophilic interaction (HILIC) stationary phases.
- **Preparative Semi-Automated HPLC:** Delivers sub-milligram to gram-scale purification of discrete peaks with high chromatographic resolution and retention reproducibility.

3. High-Resolution Dereplication and Metabolomic Profiling

To prevent the costly re-isolation of known natural products, extracts undergo early-stage dereplication prior to physical isolation:

- **UHPLC-QTOF-MS/MS & Orbitrap Mass Spectrometry:** Provides ultra-high resolving power and sub-ppm mass accuracy to calculate accurate elemental compositions and fragmentation fingerprints.
- **Global Natural Products Social Molecular Networking (GNPS):** An open-access mass spectrometry ecosystem that groups MS/MS spectra based on structural fragmentation similarities. Feature-based molecular networking connects unknowns to known spectral libraries, mapping entire structural families within an extract in hours.
- **In Silico Spectral Annotation:** Tools such as SIRIUS, CSI:Finger ID, and CANOPUS compute molecular formulas, predict functional fingerprints, and assign compound classes directly from raw fragmentation data.
- **Micro-flow and Cryoprobe NMR (^1H , ^{13}C , 2D COSY, HSQC, HMBC, NOESY):** Enables definitive structural assignment, radiochemistry determination, and stereochemical resolution on microgram-scale isolates.



Modern Screening Paradigms

Traditional screening often relied on single-enzyme inhibition assays in static buffers. However, botanical compounds frequently modulate cellular phenotypes via allosteric, epigenetic, or multi-target pathways. Modern platforms reconcile these complexities through multi-dimensional screening:

Phenotypic Profiling and High-Content Imaging

Rather than assuming an a priori molecular target, phenotypic drug discovery evaluates whether a fraction or purified compound rescues a disease-associated morphological or transcriptional state.

- **Cell Painting Assay:** Cultured cells are stained with six multiplexed fluorescent dyes that target eight distinct intracellular organelles and cellular structures (nucleus, endoplasmic reticulum, nucleoli, actin cytoskeleton, Golgi apparatus, plasma membrane, and mitochondria). Automated confocal microscopes extract thousands of morphological parameters per cell. Compounds are catalogued by their phenotypic profiles, allowing researchers to rapidly deduce biological mechanisms by comparing phenotypes to reference compound databases.
- **Transcriptomic Connectivity Mapping (L1000 / RNA-Seq):** Evaluates genome-wide expression perturbations elicited by botanical treatments. Pattern-matching algorithms match the compound's gene-expression signature against disease gene sets to infer therapeutic mechanisms and off-target effects.

High-Throughput Target-Based Assays

For defined molecular targets (e.g., GPCRs, kinases, viral proteases), high-throughput platforms screen thousands of natural extracts and pure leads simultaneously:

- **Surface Plasmon Resonance (SPR) and Bio-Layer Interferometry (BLI):** Label-free biophysical techniques that measure real-time binding kinetics, association rate constants (k_a), dissociation rate constants (k_d), and equilibrium dissociation constants (K_D) directly between immobilized protein targets and natural product mixtures.
- **Fluorescence Resonance Energy Transfer (FRET) and TR-FRET:** Microplate-based screens suitable for monitoring disruption of protein-protein interactions or enzymatic cleavages by secondary metabolites.

Pharmacological and Mechanistic Validation

Validating a bioactive lead demands demonstrating that its biological activity stems from specific target modulation rather than non-specific biochemical interference.

Target Deconvolution Techniques

When a compound shows robust phenotypic rescue, researchers deploy target identification technologies:

- **Cellular Thermal Shift Assay (CETSA):** Based on the thermodynamic principle that ligand binding alters a target protein's melting curve. Intact cells or native lysates are

incubated with the botanical compound, heated across a thermal gradient, and centrifuged to precipitate denatured proteins. Soluble fractions are quantified via Western blot or mass spectrometry (thermal proteome profiling), revealing direct intracellular target engagement without chemical modification of the natural product.

- **Drug Affinity Responsive Target Stability (DARTS):** Exploits the resistance of a ligand-bound protein to limited enzymatic proteolysis compared to its unbound counterpart.
- **Activity-Based Protein Profiling (ABPP):** Synthesizes functionalized chemical probes from the natural product core carrying a photoreactive crosslinker and a bio-orthogonal tag (e.g., an alkyne handle for click chemistry), selectively labelling and capturing true biological targets from complex native lysates.

In Vivo Efficacy and Toxicological Models

In vitro activity rarely translates directly to human physiology without intermediate animal validation:

- **Zebrafish (*Danio rerio*) Models:** Zebrafish embryos provide optical clarity, genetic tractability, and physiological homology to mammals. They serve as an intermediate translational bridge between microplate cell cultures and rodent studies, allowing researchers to simultaneously screen for teratogenicity, cardiotoxicity (QT prolongation), hepatotoxicity, anti-angiogenesis, and anti-inflammatory activity.
- **Mammalian Disease Models:** Transgenic mice and rat models confirm tissue distribution, clearance pharmacokinetics, bioavailability, target organ exposure, and behavioural or physiological endpoints.

Validation Tier	Experimental Methodology	Key Biological Readouts	Primary Strengths & Capabilities
Tier 1: Biophysical	SPR, BLI, Nano DSF, Isothermal Titration Calorimetry (ITC)	K_D , ΔH , ΔS , Binding Kinetics (k_a , k_d)	Direct, label-free confirmation of binding; excludes assay artifacts
Tier 2: Cellular & Molecular	High-Content Cell Painting, CETSA, Transcriptomic Profiling	Organelle morphology, thermal shifts, transcriptomic changes	Verifies intracellular target engagement in living cells
Tier 3: Early In Vivo	<i>Danio rerio</i> (Zebrafish) phenotypic and toxicity assays	Developmental malformations, LC_{50} , organ-specific toxicity	High throughput; real-time organogenesis and phenotype tracking
Tier 4: Preclinical In Vivo	Murine pharmacokinetics (ADME) and disease models	Bioavailability, AUC, clearance half-life ($t_{1/2}$), organ clearance	Recapitulates human organ system physiology and pathology

Synergistic Phytochemistry: Beyond the Single-Molecule Paradigm

A central tenet of Indigenous medicine is that whole-plant extracts, or polyherbal combinations, routinely demonstrate clinical actions superior to any single isolated constituent. Biomedical research often struggled with this concept, dismissing non-purified preparations as

unscientific. However, systems pharmacology and bio-chemometrics have provided a quantitative vocabulary for multi-component interaction.

Phyto-therapeutic synergy occurs through several distinct modes:

1. **Multi-Target Pharmacodynamics:** Multiple constituents weakly modulate distinct nodes in a single biological network, generating a substantial cumulative response without triggering the toxicities associated with high-dose single-target blockade.
2. **Pharmacokinetic Potentiation:** Secondary compounds that lack intrinsic activity directly enhance the absorption or delay the metabolism of primary actives. Classic examples include piperine from *Piper nigrum*, which inhibits intestinal and hepatic glucuronidation (via CYP3A4 and P-glycoprotein inhibition), dramatically augmenting the systemic bioavailability of co-administered polyphenols like curcumin.
3. **Targeted Resistance Modulation:** Bacterial efflux pump inhibitors (e.g., 5'-methoxyhydranocarpin from *Berberis* species) that disable bacterial defence mechanisms, restoring antimicrobial potency to otherwise ineffective alkaloids (berberine).

Synergistic and antagonistic dynamics are quantified computationally using the **Chou-Talalay median-effect equation** and iso-bologram analyses, calculating the Combination Index (*CI*):

$$CI = \frac{(D)_1}{(D_x)_1} + \frac{(D)_2}{(D_x)_2}$$

Where:

- $(D_x)_1$ and $(D_x)_2$ are the doses of compound 1 and compound 2 alone required to produce a specific effect level ($x\%$).
- $(D)_1$ and $(D)_2$ are the doses of each compound in combination that produce the same effect level.

A value of $CI < 1$ denotes synergism, $CI = 1$ indicates additive behavior, and $CI > 1$ denotes antagonism. Applying this rigorous mathematical framework allows researchers to validate traditional herbal mixtures as standardized botanical drugs (such as FDA-approved botanical new drug applications) rather than forcing them into artificial single-agent paradigms.

Ethical, Legal, and Socio-Cultural Dimensions

Validating traditional knowledge within Western biomedical institutions carries ethical, historical, and intellectual responsibilities. Without deliberate structural safeguards, the commercialization of Indigenous medicine risks repeating historical patterns of biopiracy and exploitation.

Key regulatory and ethical pillars include:

- **The Nagoya Protocol on Access and Benefit-Sharing (ABS):** An international agreement supplementary to the Convention on Biological Diversity (CBD). It legally binds commercial and academic researchers to obtain Prior Informed Consent (PIC) from Indigenous and local communities before collecting genetic or botanical resources, and

mandates Mutually Agreed Terms (MAT) for fair and equitable benefit-sharing (monetary royalties, local capacity building, technology transfer, and co-authorship).

- **Decolonizing Ethnopharmacological Fieldwork:** Ethnobotanists must abandon extractive research models. Studies must be co-designed with Indigenous healers, respecting cultural protocols regarding sacred or restricted knowledge.
- **Protection of Intellectual Property:** Establishing Traditional Knowledge Digital Libraries (TKDL) and open prior-art registries prevents third parties from obtaining predatory patents on long-established remedies, ensuring the originators retain sovereignty over their intellectual heritage.
- **Conservation and Ecological Sustainability:** Wild-harvesting for biomedical development can drive vulnerable plant species toward ecological depletion. Translational programs must incorporate sustainable agricultural cultivation, in vitro micropropagation, or synthetic biological reproduction (e.g., metabolic engineering in yeast or plant cell cultures) early in the developmental lifecycle.

Conclusion

Bridging Indigenous phytotherapy with modern biomedical research is not a process of validating the "primitive" with the "sophisticated." Rather, it represents the synergistic convergence of two distinct, highly informative empirical systems. Indigenous phytotherapy provides hundreds of years of documented human experiential data, holistic health paradigms, and sophisticated multi-component formulations; modern biomedicine contributes high-resolution analytical separation, phenotypic deconvolution, biophysical validation, and clinical pharmacology.

By replacing blind screening with reverse pharmacology, leveraging untargeted metabolomics and molecular networking to navigate botanical complexity, and adopting systems biology to understand phytochemical synergy, science can translate traditional cures into reproducible, globally accessible therapies. Preserving this bridge requires equal commitment to molecular rigor, ecological stewardship, and ethical justice for the Indigenous custodians of this knowledge.

References:

1. Borthakur, S. K., 1996. Wild Edible Plants in Markets of Assam, India. An Ethnobotanical Investigation. In: Ethnobiology in Human Welfare, Deep Publication, New Delhi, pp. 31-34.
2. Leonti, M., Stafford, G. I., Cero, M. D., Cabras, S., Castellanos, M. E., Casu, L., & Weckerle, C. S. (2017). Reverse ethnopharmacology and drug discovery. *Journal of Ethnopharmacology*, 198, 417–431. <https://doi.org/10.1016/j.jep.2016.12.044>
3. Khare, C. P., 2007. In: Indian Medicinal Plants, An Illustrated Dictionary, publisher: Springer Science plus Business Media, LLC., 233, Spring Street, New York, NY 10013, USA. p. 367.
4. Vaidya, A., Roy, A., & Chaguturu, R. (2018). How to rekindle drug discovery process through integrative therapeutic targeting? *Expert Opinion on Drug Discovery*, 13(10), 893–898. <https://doi.org/10.1080/17460441.2018.1514010>
5. Jain, S. K., 1991. In: Dictionary of Indian Folk Medicine and Ethnobotany.

6. Kanjilal, U. N., 1997. In: The Flora of Assam, Omsons Publications, New Delhi-110027, I(I), p. 93.
7. Khanikar, G., 2008. In: Uttam banaushadhi, 3rd ed., published by Astha Prakashan, Zoo road Tiniali, Guwahati-24, Assam, p.18.
8. Barik, S. K., Haridasan, K., Lakadong, N. J., 2007. Medicinal Plant Resources of Meghalaya: Endemism, Threat Status and Consumption Pattern, In: Envis Forestry Bulletin, 7(2).